New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

BMI has long been falling out of favor. When the American Medical Association urged downgrading BMI in 2023, it blamed its ...

An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.